$13.73
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,500 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Country

US

CEO

Mr. Douglas Bryant

IPO date

1991

Employees

6,500

ISIN

US2197981051

Key stats

Open

$13.24

Volume

1.41M

Market cap

$941.54M

Prev. close

$13.48

Impl / hst vl

-

Open interest

$0.00

$12.45

Day’s Range

$13.81

$9.92

52W Range

$35.58

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
0.35
P/B
0.53
Current ratio
1.39
Debt / Equity
1.63
ROE
-55.30%
Gross margin
43.26%
Income growth
1.20%
FCF growth
103.13

Analysts estimates

Consensus rating
Hold

The average rating from top 3 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$16.32
The top 5 analysts forecasts that 12-month price may increase by 18.86%, with a low of $12.12 and a high of $21.00
$12.12
Low
$16.32
Avg
$21.00
High
Current price

Earnings

Q2 ‘26 revenue
$630.90M
Q2 ‘26 net income
-$92.90M
Revenue
Net income
Previous EPS
$0.13
Estimate EPS
$0.21
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply